FDA 正在审查 dordaviprone (ONC201) 的新药申请 (NDA)，这是一种用于治疗复发性H3K27M突变型弥漫性胶质瘤患者的潜在疗法。 寻求加速批准 dordaviprone 的 NDA 已提交给 FDA，用于治疗复发性H3K27M突变型弥漫性胶质瘤患者。 dordaviprone 开发商 Chimerix 的首席执行官 Mike Andriole 在新闻稿中表示：“此次 ...

The trial whose results are now published was conducted with 11 patients with midline diffuse gliomas with the H3K27M mutation, with an average age of 15 years. Most of them suffered from an ...

A group led by the Department of Neurosurgery, Brain Research Institute, Niigata University succeeded in the diagnosis of leptomeningeal disease in diffuse midline gliomas by detecting H3K27M ...